These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 17760738

  • 1. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I.
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 8. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.
    Antivir Ther; 2006 Oct; 11(1):53-62. PubMed ID: 16518960
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G.
    Antivir Ther; 2008 Oct; 13(7):901-7. PubMed ID: 19043924
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [Abstract] [Full Text] [Related]

  • 15. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
    [Abstract] [Full Text] [Related]

  • 16. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Apr; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 17. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M, Walli RK, Breske A, Kruse G, Stocker H, Banik N, Richter H, Mazur D.
    AIDS; 2007 Jun 19; 21(10):1368-70. PubMed ID: 17545717
    [Abstract] [Full Text] [Related]

  • 18. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna GJ.
    J Clin Pharmacol; 2008 May 19; 48(5):553-62. PubMed ID: 18440920
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.
    Clin Ther; 2008 Oct 19; 30(10):1794-805. PubMed ID: 19014835
    [Abstract] [Full Text] [Related]

  • 20. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep 19; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.